Recombinant peptide hormone

Serelaxin

Serelaxin is a recombinant form of human relaxin-2. It is distinct from relaxin-3 and other family members. Its literature allows comparison of preclinical mechanisms with human results that did not confirm all early signals.

This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.

Receptor, selectivity and context

Record the receptor panel actually measured. Absence of a result for another receptor does not establish absence of activity.

Which receptor subtype and species were evaluated?
Was affinity, functional potency or an integrated response measured?
Does the comparison include the alternative receptors needed for a selectivity claim?

Find readings for this question

Mechanism described in the literature

In cultured human cardiac myofibroblasts and mice with experimental cardiac injury, serelaxin was associated with changes in TLR-4- and NLRP3-inflammasome-related signaling. Pharmacological controls supported nNOS involvement; these findings do not establish equivalence to human cardiovascular outcomes.

Other names in the literature

Serelaxin
Recombinant human relaxin-2

A mechanism must retain its experimental stimulus

The cellular work used a defined combination of stimuli to examine inflammatory responses and collagen deposition in vitro. The results belong to that induced culture state. Naming a compound and a pathway is insufficient without the perturbation applied and the indicators compared.

The initial trial differed by outcome measure

In RELAX-AHF, involving people hospitalized with acute heart failure, serelaxin showed a favorable difference in one primary dyspnea measure but not the other. The mortality signal was an additional outcome. Presenting all these observations as equivalent confirmations would erase the analytical hierarchy.

The larger follow-up did not confirm its primary outcomes

RELAX-AHF-2, a later and larger human investigation, found no significant difference from placebo in cardiovascular death or early worsening of heart failure. This negative result belongs in the evidence assessment. A plausible molecular explanation and an early signal do not replace testing the selected clinical outcomes.

Questions and answers

Are serelaxin and relaxin-3 the same entity?

No. Serelaxin is recombinant human relaxin-2, not relaxin-3.

Did the later trial confirm all the initial signals?

No. RELAX-AHF-2 did not find significant differences in its two primary outcomes.